trastuzumab deruxtecan,ruxolitinib
novartis,daiichi sankyo,incyte,astrazeneca
['gyn', 'trastuzumab deruxtecan', 'rux,(-crux),(-trux)', 'solid tumor', 'pantumor', 'destiny,pantumor02', 'pancsm']
in the phase 2 destiny-pantumor02 trial, trastuzumab deruxtecan elicited clinical activity across a range of her2 expressing solid tumors. #oncology #nursing #gyncsm #pancsm #asco23 
Capturing the voice of nursing professionals in the oncology news landscape.